WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of ...

Companies at the forefront of the first major breakthroughs in AI are already up 25,000%. If you don’t want to miss what could be the next wave of AI growth, simply enter your email address to ...

Q2 2026 Earnings Call November 10, 2025 4:30 PM ESTCompany ParticipantsSteven Lisi - CEO & Chairman of the BoardDouglas Larson ...

WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceed ...